Connor Clark & Lunn Investment Management Ltd. Sells 202,917 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA)

Connor Clark & Lunn Investment Management Ltd. cut its holdings in shares of ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 25.6% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 588,874 shares of the biotechnology company's stock after selling 202,917 shares during the period. Connor Clark & Lunn Investment Management Ltd. owned approximately 0.25% of ADMA Biologics worth $11,772,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in ADMA. Bank of Montreal Can acquired a new stake in shares of ADMA Biologics in the 2nd quarter worth approximately $17,886,000. D. E. Shaw & Co. Inc. raised its holdings in ADMA Biologics by 26.8% during the second quarter. D. E. Shaw & Co. Inc. now owns 6,824,517 shares of the biotechnology company's stock worth $76,298,000 after purchasing an additional 1,442,799 shares in the last quarter. Principal Financial Group Inc. lifted its position in ADMA Biologics by 785.7% in the third quarter. Principal Financial Group Inc. now owns 1,194,221 shares of the biotechnology company's stock worth $23,872,000 after purchasing an additional 1,059,394 shares during the period. Castleark Management LLC bought a new position in ADMA Biologics during the 1st quarter valued at $5,400,000. Finally, First Turn Management LLC acquired a new position in shares of ADMA Biologics during the 3rd quarter valued at $13,293,000. 75.68% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

ADMA has been the subject of several research analyst reports. HC Wainwright upped their price objective on ADMA Biologics from $18.00 to $26.00 and gave the company a "buy" rating in a report on Friday, November 8th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $20.00 price objective on shares of ADMA Biologics in a research note on Friday, September 20th. Finally, Raymond James increased their target price on shares of ADMA Biologics from $18.00 to $25.00 and gave the company a "strong-buy" rating in a research note on Friday, November 8th.

Insider Buying and Selling at ADMA Biologics

In other news, CEO Adam S. Grossman sold 236,889 shares of the firm's stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $17.69, for a total value of $4,190,566.41. Following the sale, the chief executive officer now directly owns 2,059,726 shares of the company's stock, valued at approximately $36,436,552.94. This trade represents a 10.31 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, COO Kaitlin M. Kestenberg-Messina sold 24,150 shares of the business's stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $16.90, for a total value of $408,135.00. Following the transaction, the chief operating officer now directly owns 449,088 shares of the company's stock, valued at $7,589,587.20. This represents a 5.10 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 406,900 shares of company stock worth $7,128,521 over the last 90 days. Insiders own 3.70% of the company's stock.

ADMA Biologics Trading Down 0.6 %

NASDAQ ADMA traded down $0.12 on Friday, hitting $21.18. 2,069,445 shares of the company were exchanged, compared to its average volume of 3,636,930. The company's 50 day moving average price is $18.80 and its 200-day moving average price is $14.73. The firm has a market capitalization of $5.01 billion, a P/E ratio of 76.07 and a beta of 0.64. ADMA Biologics, Inc. has a twelve month low of $3.60 and a twelve month high of $23.64. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last issued its earnings results on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share for the quarter, beating analysts' consensus estimates of $0.13 by $0.02. The company had revenue of $119.84 million for the quarter, compared to the consensus estimate of $107.25 million. ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. During the same quarter in the prior year, the company earned $0.01 EPS. Analysts predict that ADMA Biologics, Inc. will post 0.52 earnings per share for the current fiscal year.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.